Prothena | PRTA - 流动资产



金融业
股票价格
USD
资产
USD 302.58M
现金及等价物
USD 288.19M
销售成本
USD 28.94M
流动资产
USD 292.01M
流动负债
USD 11.66M
债务
USD 7.65M
EBIT
USD 25.79M
EBITDA
USD 25.98M
员工
163
EPS每股收益
USD 0.6
股本和储备
USD 286.89M
销售毛利
USD 51.08M
债务利息支出
USD 302.58M
利息收入
USD 2.42M
贷款资金
USD 0
市值
USD 477M
净收入
USD 32.72M
营业费用
USD 25.29M
营业利润
USD 25.79M
普通股股本
USD 53.08M
PE价格收益
22.11
税前利润
USD 32.72M
销售收入
USD 51.08M
销售和管理费用
USD 12.67M
贸易债权人
USD 1.94M
应收帐款人
USD 5.16M


流动资产 更改 日
Acadia Pharmaceuticals USD 1.22B 128.53M 2026-06
Agios Pharmaceuticals USD 717.67M 117.18M 2026-06
Akebia Therapeutics USD 229.55M 13.93M 2026-06
ALKERMES USD 1.52B 164.26M 2026-06
Alnylam Pharmaceuticals USD 4.62B 400.86M 2026-06
Amgen USD 34.96B 3.49B 2026-06
Biogen USD 7.31B 1.88B 2026-06
BioMarin Pharmaceutical USD 3.97B 633.45M 2026-06
Exelixis USD 1.25B 42.18M 2026-06
Immunic USD 188.76M 165.89M 2026-03
Incyte USD 6.03B 542.31M 2026-06
Ionis Pharmaceuticals USD 2.49B 446.73M 2026-06
MacroGenics USD 321.69M 139.16M 2026-06
Nektar Therapeutics USD 589.04M 322.77M 2026-03
Neurocrine Biosciences USD 1.64B 798.6M 2026-06
Prothena USD 292.01M 47.19M 2026-06
Regeneron Pharmaceuticals USD 18.45B 236.8M 2026-06
Ultragenyx Pharmaceutical USD 606M 51M 2026-06
Vertex Pharmaceuticals USD 12.54B 813.4M 2026-06